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Abstract: 
We report here the long-term results of HLA mismatched kidney transplantation 
without maintenance immunosuppression (IS) following combined kidney and 
bone marrow transplantation (CKBMT). The first three subjects were treated with 
nonmyeloablative conditioning and an 8-14 month course of calcineurin inhibitor 
(NKD03). The next two subjects received, in addition, two doses of pre-transplant 
rituximab (mod NKD03).  The last five recipients received two pre and two post-
transplant rituximab doses (ITN036). All 10 subjects developed transient 
chimerism and in seven of these, IS was successfully discontinued.  Four 
subjects continue to be IS free for periods of 4.3-11.2 years, while three required 
IS after 6-8 years due to recurrence of original disease or chronic allograft 
glomerulopathy. Donor-specific antibody (DSA) was detectable in some 
recipients treated with the NKD03 and mod NKD03 regimens. In contrast, no 
DSA was detected in ITN036 subjects, who showed more consistent and durable 
B cell depletion, despite high BAFF levels.  In conclusion, long-term stable kidney 
allograft survival without maintenance IS can be achieved following transient 
mixed chimerism induction.  Adequate B cell depletion during the initial 6 months 
appears to be an important factor in preventing development of de novo DSA.  
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 Introduction: 
          Short-term results following organ transplantation have been significantly 
improved by the use of increasingly efficacious immunosuppressive agents. 
However, their chronic administration results in significant morbidity, especially 
from an increased incidence of cardiovascular disease(1),  infection(2),  
malignancies(3),  de novo diabetes(4) and other metabolic derangements.  
Unfortunately, the potent immunomodulatory effects of current therapeutic 
protocols do not prevent the development of chronic rejection, despite their 
administration being pushed to toxic levels. Therefore, induction of tolerance, 
defined as the absence of destructive immune responses to a transplanted tissue 
without ongoing immunosuppressive therapy, remains the ultimate goal of organ 
transplantation.  
          Since the seminal work reported by Billingham, Brent and Medawar on 
neonatal tolerance in 1956, numerous tolerance induction strategies have been 
defined in rodents. However, only a very limited number of these strategies have 
been successfully translated to large animals and even fewer to primates. Among 
the few protocols that have been applied successfully in humans, induction of 
donor chimerism, either transient or permanent, currently appears to be the most 
promising strategy to achieve renal allograft tolerance. Initial results of clinical 
trials for tolerance induction in three centers have so far been reported.  Using 
TLI and DBMT, the Stanford group reported successful induction of stable 
chimerism and renal allograft tolerance in the majority of HLA-identical kidney 
transplant recipients(5-7).  More recently, Leventhal et al. at Northwestern have 
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reported the use of an intensive conditioning regimen and donor hematopoietic 
stem cells for induction of full donor chimerism and tolerance in HLA-mismatched 
kidney transplant recipients(8).  Although the follow-up of these patients is still 
relatively brief, persistent donor chimerism without GVHD has been reported, 
allowing weaning from all maintenance immunosuppression by 1 year in 
approximately half of the patients.   
         At Massachusetts General Hospital, based on decades-long basic studies 
in animal models(9-12),  we have applied combined kidney and donor bone 
marrow transplantation (CKBMT) for induction of allograft tolerance in both HLA 
matched(13-15) and HLA-mismatched(16,17)  kidney transplant recipients.  In 
this report, we summarize our experience in all 10 subjects, present assays of 
their anti-T cell responses, B cell depletion and BAFF levels and evaluate the 
potential relationship between the conditioning regimens and long-term humoral 
responses. Our observations emphasize the importance of adequate B cell 
depletion during the initial 6 months to inhibit de novo DSA. 
 
METHODS 
Study subjects:  
A total of 10 subjects, age 22-46, 6 males and 4 females, were enrolled into 
these studies.  Their original kidney diseases include Alport’s syndrome (n=4), 
polycystic kidney disease (n=2), membrano-proliferative glomerulonephritis 
(MPGN) type 1(n=2), reflux uropathy (n=1) and focal glomerulosclerosis (n=1) 
(Table 1). The first three subjects (#1 - #3) received the NKD03 conditioning 
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regimen; the next two subjects (#4 and #5) received the modified NKD03 
regimen. The last five subjects(#6 - #10) received the ITN036 protocol detailed in 
Fig. 1.  
Conditioning Regimen:  The initial conditioning regimen (Fig. 1, NKD03) 
consisted of cyclophosphamide (60 mg/kg/d) administered i.v. on days –5 and –4 
with respect to transplantation; humanized anti-CD2 mAb (MEDI 507, 
MedImmune Inc., Gaithersburg, MD) at a  test dose of 0.1 mg/kg on day -2 
followed  by 0·6 mg/kg/dose on days  -1, 0 and +1; cyclosporine A (CyA, Novartis 
Pharmaceuticals Inc., East Hanover, NJ) (5 mg/kg) i.v. on day –1; and thymic 
irradiation (700 cGy) on day –1. Hemodialysis was performed before and 14 
hours after each dose of cyclophosphamide. On Day 0, kidney transplantation 
was followed by i.v. infusion of unprocessed donor bone marrow (DBM). Oral 
CyA (Neoral, Novartis Pharmaceuticals, Inc.) was administered postoperatively 
at 8 to 12 mg/kg/day with target trough blood levels of 250-350 ng/ml, then 
tapered and discontinued over several months.   
 The protocol was modified after treatment of the third subject (see 
Results), with the addition of Rituximab, 375 mg/m²/dose on days -7 and -2; and 
prednisone, 2 mg/kg/d starting on the day of transplantation and tapering to 
withdrawal over the next 10 post-transplant days (Fig. 1,modified NKD03). Since 
subjects treated with this modified NKD03 regimen still developed donor-specific 
antibodies (DSA) after discontinuation of immunosuppression, the regimen was 
further modified (Fig.1) to add two more doses of Rituximab (375 mg/m²/dose) on 
days 5 and 12, plus a more prolonged course of prednisone until day 20, and 
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tacrolimus in place of CyA (ITN036). Tacrolimus was slowly tapered over several 
months and completely discontinued at 8 months after confirming no rejection by 
a 6 month protocol biopsy.  All treatment regimens were approved by the 
Massachusetts General Hospital Institutional Review Board (IRB) and developed 
in collaboration with the Immune Tolerance Network (ITN). 
 Biopsies.  Kidney allograft biopsies were taken per protocol at day 0 and 
at months 6, 12, 24 and 36.  Some subjects had later protocol biopsies after 5-8 
years of follow-up.  Indication biopsies were taken for any episode of graft 
dysfunction.  All biopsies were processed for routine light microscopy, 
immunofluorescence (including C4d stains) and electron microscopy by 
techniques previously reported (16, 18). 
 In Vitro Immunologic Assays: Standard MLR and CML assays were 
performed using the methods detailed previously.(14)  LDA to quantify cytotoxic 
T-lymphocyte precursor frequencies and IL-2-producing Th frequencies were 
performed as described(19). 
 Detection of donor-specific antibodies: Serially collected pre- and post- 
transplant sera samples were tested for the presence of HLA antibodies using 
ELISA kits (LAT Class I & II, One Lambda, Canoga Park, CA).  
 Serum BAFF measurement: Concentration of BAFF in the serum was 
measured using a Quantikine ELISA kit (R&D systems, Minneapolis, MN) 
according to the manufacturer’s instructions. Serum samples were diluted 1:8 in 
PBS. 
 
8 
 
RESULTS:   
 Induction of transient chimerism:  As in the previously reported patients, 
all additional subjects developed transient multilineage mixed chimerism, which 
became undetectable by 2-3 weeks post-CKBMT(16, 20). Opmerking [CU1]: Strange page 
break here 
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 Acute kidney injury (AKI) 10-14 days after DBMT: We previously 
described the cytokine syndrome-like manifestations observed after CKBMT as 
“engraftment syndrome” (16, 18).  In fact, the symptoms have been temporally 
associated with the loss of peripheral chimerism as well as of the return of host-
derived hematopoietic elements. The most troublesome manifestation of this 
syndrome, and the only manifestation not alleviated by addition of steroids to the 
post-transplant treatment regimen, was acute kidney injury (AKI), which was 
observed after day 10 in all patients, although minimally in Subject #1. The 
biopsies taken during AKI showed endothelial injury with CD8+ T cell infiltration, 
as reported previously in detail(18).  The peak serum creatinine (Cr.) level 
ranged from 3·5 to 15·4 mg/dl during days 10-20. Among the ten subjects who 
developed AKI, four recovered without additional treatment.  Renal allograft 
function was normalized in two subjects in conjunction with Thymoglobulin and 
plasma exchange, in one with Thymoglobulin alone and in one with additional 
steroid therapy. Two kidney allografts failed to recover, one in association with 
humoral rejection due to preformed anti-donor antibody (Subject #3) and one that 
developed thrombotic micro-angiopathy associated with high tacrolimus levels 
(Subject #8). 
 Long-term clinical course of subjects in NKD03 (Subjects #1-5):  
Initial results, after follow-up periods of up to 2-5 years, in the first five patients, 
were previously reported(16).  As in that report, except for Subject #3, who was 
retrospectively found to have DSA prior to transplant and suffered early graft 
failure due to acute antibody-mediated rejection, all renal allografts are functional 
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with the longest survival now exceeding 11 years (Subject #1). Four protocol 
biopsies performed in Subject #1 up to 7·5 years after CKBMT showed no 
evidence of rejection, including the absence of C4d deposition (Figs. 3A-C). 
Subject #2 was successfully tapered off of IS by 14 months, after treatment for 
suspected humoral rejection (transient C4d deposition without DSA) at around 
day 45.  He remained stable until year 7 following immunosuppression 
withdrawal (Fig. 2). At that point, urinary protein first became detectable. Allograft 
biopsy revealed no rejection but recurrence of his original disease, MPGN type I 
(C3 glomerulopathy) (Figs. 3D-F). Mycophenolate mofetil (MMF) monotherapy 
for recurrent MPGN was initiated after the 8th year. Although he has been 
inconsistently compliant, he is currently stable (serum creatinine 2.1 mg/dl) (Fig. 
2) with minimal urinary protein (200-300 mg/L).  Subject #3 had shown high PRA 
(50%) but did not show DSA by ELISA and crossmatch was negative before 
transplantation. However, he lost his renal allograft with severe acute humoral 
rejection on day 10 (Fig. 2). Retrospective analysis with LUMINEX revealed 
preformed DSA against HLA class I (FIG. 4A) and his humoral rejection was 
retrospectively concluded to be due to preformed DSA. This subject 
subsequently underwent successful second transplantation with conventional IS. 
Subject #4 received the modified NKD03 regimen (Fig. 1). Protocol biopsies as 
early as 11 months and up to day 731 stained positive for C4d(16),  but did not 
have features of active rejection.  However, his five-year protocol biopsy revealed 
glomerular basement membrane duplication by light and electron microscopy 
with capillaritis and continued C4d deposition with minimal interstitial fibrosis (Fig. 
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3I). Although his renal function was stable with serum creatinine 1.6 at that time 
(Fig. 2), MMF was initiated 6 years after IS had been withdrawn. Since 
proteinuria became detectable after 7 years post-transplant and his kidney 
function has been slowly deteriorating, a brief course of IVIG and rituximab were 
administered and MMF has recently been switched to belatacept (Fig. 2) to 
prevent further progression of chronic rejection. Subject #5 remained stable for 5 
years (Fig. 2) with no evidence of rejection or C4d deposition, despite intermittent 
detection of weak DSA after 3 years (Fig.4). Subsequently, after suffering 
multiple severe episodes of gout, his renal function deteriorated and C4d 
deposition transiently became detectable in the biopsy at 6 years. Despite a 
protocol biopsy at 6.3 years that showed minimal transplant glomerulopathy (cg1) 
(Figs. 3J, K) with negative C4d staining (Fig. 3L), renal function became unstable 
with serum Cr. level 2.3-2.8 mg/dl after the 7th year (Fig. 2) and Belatacept has 
recently been initiated.  
 
 Clinical course of subjects in ITN036 (Subjects #6-10):   Subject # 6 
developed the typically observed AKI after day 10 and recovered without 
additional treatment. His IS was slowly tapered and completely discontinued at 8 
months after CKBMT. He is currently doing well with a serum Cr. level of 1.5 
mg/dl for almost 5 years after transplantation, without ongoing IS (Fig. 2). His 
biopsies have shown no evidence of rejection (Figs.3M and N) but showed de 
novo C4d deposition in a biopsy taken at 2 years (Fig.3O).  Immunosuppressive 
therapy for Subject #7 was discontinued at 8 months. She is currently 4.7 years 
Opmerking [CU2]: It seems strange 
to mention 2 years and not the ensuing 
3 years.  Did C4d persist? 
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after CKBMT with normal kidney function (serum Cr. 0.8 mg/dl) (Fig. 2) with no 
evidence of rejection or C4d staining in the 2-year protocol biopsy (Figs. 3P-R). 
Subject # 8 failed to recover from AKI. Biopsy performed on day 22 revealed 
arterial intimal matrix expansion with infiltrating mononuclear cells and arterial 
fibrinoid necrosis without C4d deposition in peritubular capillaries. No DSA was 
detectable.  Differential diagnosis included acute cellular rejection type III versus 
intra-renal thrombotic microangiopathy, possibly due to tacrolimus toxicity. 
Tacrolimus was discontinued and three doses of anti-thymocyte globulin were 
administered with MMF. Despite these treatments, her kidney function gradually 
failed and she was returned to CAPD at 7 months after transplantation. Subject 
#9 developed a transient AKI after day 10 and recovered without additional 
treatment. Her immunosuppression was slowly tapered and was discontinued at 
8 months after transplantation. She is currently well at almost 4.3 years after 
CKBMT with normal kidney function (serum Cr. 1·0 mg/dl)(Fig. 2). The protocol 
biopsy at 2 years showed no evidence of rejection (Figs.3S-U). In Subject #10, 
kidney function gradually returned to normal by 2 months after AKI and a 6-
month protocol biopsy did not show rejection. His immunosuppression was 
discontinued at 8 months. One month later, he developed acute allograft 
pyelonephritis with moderately elevated serum Cr. (2·2 from 1·6 mg/dl). This was 
treated with antibiotics and the kidney function recovered to base line. However, 
3 weeks after the resolution of his infection, he developed severe acute cellular 
rejection (Banff 2B)(Fig. 3V) with no C4d deposition (Fig. 3X).  Several DSA 
assays were negative. He was treated with steroid pulses and anti-thymocyte 
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globulin, following which his renal function improved but never fully recovered 
(Fig. 2).  A renal biopsy 6 months later showed interstitial and intimal fibrosis 
without active inflammation (Fig. 3W).  His kidney function remained 
compromised thereafter and he recently received a successful second kidney 
transplant with conventional IS at 3 years after CKBMT.  
 
 Anti-donor T cell responses:   MLR, CML, CTLp and HTLp assays in 
NKD03 subjects were previously reported.(16, 21)  All NKD03 subjects 
developed donor specific nonresponsiveness (DSN) by 3 to 9 months in these 
assays. Serial in vitro immunological assays to test anti-donor T cell responses 
were also performed in the four ITN036 subjects who discontinued their 
immunosuppression.  In these subjects, DSN or donor-specific hyporespon-
siveness (DSH) also developed in MLR by 3 to 18 months, but anti-donor 
responses were again evident at 18-36 months in Subjects #7 and #9 (Table 2).  
 
 High incidence of DSA production in the modified NKD03 subjects:         
DSA has never been detected in Subjects #1, 6, 7, 8, 9 and 10. DSA was 
transiently detected only once in Subject #2 with no evidence of rejection.  Anti-
HLA class II DSA has been persistently positive in Subject #4, and was 
associated with persistent C4d deposition and glomerulopathy. In Subject #5, 
weak anti-class II DSA has been detected intermittently after 3 years with 
transient C4d deposition (Fig. 3).  In ITN036 subjects, no DSA has been 
detectable even in Subject #10 who developed severe acute cellular rejection.  
Met opmaak: Markeren
Met opmaak: Markeren
Opmerking [CU3]: Please look at 
Table 2- the last time point has been 
removed for Pts 6,7 and 9, making this 
statement seem untrue.  Please replace 
with the table version I will send with 
these comments. 
Met opmaak: Markeren
Met opmaak: Markeren
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 B cells (CD3-CD19+) were almost completely eliminated from the 
circulation for 6 months in ITN036 subjects:  Recovery of CD3-CD19+ cells in 
the two subjects (#1 and #2) after treatment with the original NKD03 regimen 
was observed by days 50 and 100, respectively.  With two doses of pre-
transplant rituximab (modified NKD03), depletion of CD3-CD19+ cells was 
extended to day 150 (Subjects #4 and #5) but complete loss of CD3-CD19+ cells 
from the peripheral blood was not observed. In contrast, peripheral blood CD3-
CD19+ cells were less than 1-2/mm3 for 6 months in all five ITN036  subjects 
treated with 4 doses of peritransplant rituximab (Fig. 45).(20)  
 
 High serum BAFF levels in the recipients treated with rituximab:  
Serum BAFF levels were less than 2 ng/ml at all time points assessed in Subject 
#1. Subject #2 had high BAFF levels initially until day 100 and humoral rejection 
was suspected at around day 45, when his BAFF level was highest (Fig. 5B, 
arrow). BAFF levels waned thereafter to less than 2 ng/ml after day 100 and he 
successfully discontinued his IS. In contrast, high BAFF levels were detected 
over 300 days in two subjects treated with the modified NKD03 regimen. 
Persistently high BAFF was also detectable for more than 300 days in the 
ITN036 subjects (Fig. 4).  
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DISCUSSION 
           We report here that induction of long-term (greater than11 years) stable 
renal allograft function without maintenance immunosuppression can be 
achieved after induction of transient lymphohematopoietic chimerism in 
approximately one-half of recipients of HLA-mismatched CKBMT.  Consistent 
with the fact that chimerism in these recipients was transient, there has been no 
GVHD observed in our preclinical (10, 11) or clinical studies(16),  which is an 
attractive attribute of this approach for tolerance induction. Apparently, the 
mechanism of tolerance induction after transient chimerism in nonhuman 
primates and humans differs from that observed in murine mixed chimerism 
models, where central deletional pathways have been demonstrated in 
conjunction with chimerism that persists indefinitely.(12, 22).(9, 23)  Nevertheless, 
our NHP studies have consistently demonstrated the necessity for DBM 
engraftment, resulting in at least transient measurable donor chimerism, 
especially in lymphoid lineages, for successful induction of tolerance(10, 11, 24).  
Our nonhuman primate studies have shown that co-stimulatory blockade, with 
agents directed against CD40/CD154(11) or B7/CD28 (manuscript in 
preparation) were important in achieving consistent  tolerance. In these clinical 
trials, we have used an anti-CD2 monoclonal antibody (MEDI507) which provides 
both T-cell depletion and co-stimulatory blockade via the CD2/LFA-3 interaction 
in our clinical protocol(16).  Our preclinical studies have also emphasized that the 
kidney allograft itself plays a critical role in the induction and maintenance of 
tolerance. In our studies in NHP, the same conditioning regimen that achieves 
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renal allograft tolerance after induction of transient chimerism, has consistently 
failed to induce tolerance of isolated heart allografts in monkeys(25). However, 
heart allograft tolerance is regularly achieved by co-transplanting the kidney from 
the same donor(26). Moreover, patients who lost chimerism after receiving the 
same regimen as NKDO3 and BMT  for hematologic malignancies , but without a 
kidney transplant, failed to develop donor-specific hyporesponsiveness (19), in 
marked contrast to those receiving kidney transplantation with the same BMT 
regimen (21). We hypothesize that generation of donor-specific regulatory cells in 
the thymus during the original chimeric state is a process that is maintained 
bycombined with continueding interactions of recipient T cells with as yet 
undefined donor cells or antigens in the kidney allograft and is responsible for 
maintenance of the tolerance (21). One potentially important renal cell is the 
renal tubular epithelial cell, that has been reported to participate in the induction 
of allospecific tolerance in rodents and, by in vitro assays in humans (27-29).  
Studies are in progress in our laboratories to assess the possible role of this cell 
in the NHP tolerance model upon which these clinical studies are based. 
          Despite the encouraging results of successful long-term IS-free renal 
allograft survival in our initial clinical trials, obstacles remain before we anticipate 
more widespread application of this approach.   The first obstacle is acute kidney 
injury (AKI) that has been observed at approximately day 10 in all subjects, 
although minimally in Subject #1.  We have previously reported this complication 
as “engraftment syndrome” which has been described previously following both 
autologous and allogeneic bone marrow transplantation (30).  However, 
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“engraftment syndrome” may not adequately describe the phenomenon we have 
observed, since it was always associated both with recovery of host 
hematopoietic cells, potentially including homeostatic recovery of memory T cells, 
and with rapid loss of chimerism.  We have noted that the AKI of engraftment 
syndrome has never been observed in our MHC-mismatched NHP model, in 
which chimerism is also lost, but at a more gradual pace, usually over 2-3 
months(10, 11, 31).  Our current interpretation of this observations is that the pre-
transplant cyclophosphamide-based regimen chosen for the clinical trials(16),  in 
place of low dose total body irradiation (TBI) used in the NHP preparative 
regimen(10, 11, 31, 32), may be less effective in preventing rapid homeostatic 
recovery of host memory T cells, which, when rapidly expanding, may have had 
destructive effector function at the level of donor renal endothelial cells.  This 
hypothesis is consistent with the observation of CD8 T cell activation immediately 
following conditioning (18) and the appearance of CD8 T cells in peritubular 
capillary endothelial cells during the period of AKI (18).  For this reason, in a 
current modification of our CKBMT protocol, we are testing the effect of 
substituting a low dose of TBI for pre-transplant cyclophosphamide (in progress). 
  
        Also, although the phenomenon of engraftment syndrome has been 
observed in autologous and allogeneic bone marrow transplantation [  ], the AKI 
observed in those cases was much milder than that observed in our protocol.  
One likely reason for this difference is that in the former cases, the recipients had 
normal kidneys, while the recipients of our CKBMT protocol had also just 
18 
 
received a kidney transplant, with attendant inflammatory changes which would 
likely make it more susceptible to any additional injury during the early post-
transplant period.  Concurrent calcineurin inhibitor toxicity would undoubtedly 
also contribute to renal dysfunction, and it is likely that the combination of 
tacrolimus toxicity and engraftment syndrome contributed heavily to the renal 
failure from TMA observed in Subject # 8.  In our modified protocol, we will 
therefore discontinue treatment with calcineurin inhibitors during the duration of 
engraftment syndrome, should it occur despite the change from 
cyclophosphamide to irradiation in the preparative regimen. 
  
 Another obstacle, observed especially in the modified NKD03 subjects, 
was the frequent development of either transient or persistent DSA, despite 
specific loss of anti-donor T cell responses. As depletion of B cells enhances B 
cell activating factor (BAFF) production which has been found to significantly 
enhance the differentiation of marginal zone B cells into immunoglobulin 
secreting cells in a T cell dependent manner(33), we measured peripheral blood 
B cells (CD19+) and serum BAFF levels after transplantation.  In Subject #2, 
humoral rejection, suspected around day 45 while tapering IS, was associated 
with high BAFF levels (>8 ng/ml). His BAFF levels subsequently waned to the 
baseline level by day 100 and IS was successfully withdrawn without DSA 
development. In the two modified NKD03 subjects, B cells were not completely 
depleted and recovered within 6 months. In addition, persistently high serum 
BAFF levels were detected in these patients, which may have contributed to 
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enhanced DSA production.  In contrast to the results in the modified NKD03 
protocol, the intensified anti-B cell treatment included in the ITN036 regimen was 
associated with almost no evidence of DSA production. In these ITN036 subjects, 
although BAFF levels were elevated similarly to those observed in the modified 
NKD03 patients, peripheral blood B cells were essentially nondetectable for more 
than 6 months and there was no development of DSA. Thus, high BAFF levels 
may not be a risk factor for DSA production if  B cells are profoundly depleted.  
 Although anti-HLA antibodies are thought to represent T cell-dependent 
responses, we found no apparent relationship between DSA production and anti-
donor T cell responses in these clinical studies.  Thus, modified NKD03 subjects 
developed DSA despite undetectable anti-donor T cell responses and Subjects 
#7 and #9 in ITN036 have not developed DSA despite persistent anti-donor CTL 
responses.    Our clinical observations therefore suggest that B cell depletion for 
6 months by rituximab, as achieved in the ITN036 subjects, may avoid the DSA 
obstacle to tolerance induction via the mixed chimerism approach. In this regard, 
we are currently investigating a conditioning regimen that combines B cell 
depletion and anti-BAFF antibody in nonhuman primates.  
 In conclusion, our clinical studies have shown that immunosuppression-
free stable renal allograft function can be achieved in HLA-mismatched donor-
recipient pairs,  with follow up times  of greater than 11 years, by induction of 
transient chimerism through DBMT.  We hope that the relatively small 
modifications of the protocol we have described will avoid the remaining 
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obstacles to more widespread application of this technology for clinical tolerance 
induction.  
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Figure Legends 
Fig. 1:  Nonmyeloablative conditioning regimens. 
The initial conditioning regimen (Fig. 1, NKD03) consisted of cyclophosphamide 
(60 mg/kg/d) administered i.v. on days –5 and –4 with respect to transplantation; 
humanized anti-CD2 mAb (MEDI 507, MedImmune Inc., Gaithersburg, MD) (0·6 
mg/kg/dose) on days -2, -1, 0 and +1; cyclosporine A (CyA, Novartis 
Pharmaceuticals Inc., East Hanover, NJ) (5 mg/kg) i.v. on day –1; and thymic 
irradiation (700 cGy) on day –1. Hemodialysis was performed before and 14 
hours after each dose of cyclophosphamide. On Day 0, kidney transplantation 
was followed by i.v. infusion of unprocessed donor bone marrow (DBM). Oral 
CyA (Neoral, Novartis Pharmaceuticals, Inc.) was administered postoperatively 
at 8 to 12 mg/kg/day with target trough blood levels of 250-350 ng/ml, then 
tapered and discontinued over several months.   
The protocol was modified after treatment of the third subject (see Results), with 
the addition of Rituximab, 375 mg/m²/dose on days -7 and -2; and prednisone, 2 
mg/kg/d starting on the day of transplantation and tapering to withdrawal over the 
next 10 post-transplant days (modified NKD03). Since subjects treated with this 
modified NKD03 still developed donor specific antibodies (DSA) after 
discontinuation of immunosuppression, the regimen was further modified (Fig.1) 
to add two more doses of Rituximab (375 mg/m²/dose) on days 5 and 12, plus a 
more prolonged course of prednisone until day 20, and tacrolimus in place of 
CyA (ITN036). Tacrolimus was slowly tapered over several months and 
completely discontinued at 8 months after confirming no rejection by a 6 month 
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protocol biopsy.  All treatment regimens were approved by the Massachusetts 
General Hospital Institutional Review Board (IRB) and developed in collaboration 
with the Immune Tolerance Network (ITN). 
The initial preparative conditioning regimen (NKD03) consisted of 
cyclophosphamide (60 mg/kg/d)  on days –5 and –4, humanized anti-CD2 mAb  
(0·6 mg/kg/dose) on days -2, -1, 0 and +1; cyclosporine A targeting trough levels 
of 250-300 mg/ml  beginning on day –1; and thymic irradiation (7Gy) on day –1. 
Kidney transplantation was followed by i.v. infusion of donor bone marrow 
(DBM). CyA was tapered and discontinued over 9-14 months.   
In the modified NKD03 regimen, administration of Rituximab (375 mg/m²/dose) 
on days -7 and -2 and a short course of post-transplant prednisone were added.  
In the ITN036 regimen, two more dose of Rituximab (375 mg/m²/dose)  on days 
+5 and +12 and a longer course of prednisone were added and post-transplant 
cyclosporine was replaced with an 8 months course of tacrolimus, targeting 
trough levels of 8-12 ng/ml.  
Fig. 2: Clinical course after CKBMT 
Blue lines indicate serum Creatinine levels (mg/dl) after CKBMT. Green bars 
indicate induction immunosuppression (CyA:cyclosporine, Tac:tacrolimus). 
Orange /blue bars indicate reinstitution of maintenance immunosuppression 
(MMF: mycophenolate mofetil, actino: actinomycin, Pred: prednisone), CTLA4Ig 
(belatacept). 
Fig. 3: Late renal allograft biopsies (all protocol biopsies unless noted). 
24 
 
A-C (Subject #1 at 7.5 years):  Protocol biopsy shows no evidence of rejection 
by light microscopy (LM) (A).  The glomeruli are normal by electron microscopy 
(EM) (B) and no C4d staining is detectable by immunofluorescence (IF)( C) 
D, E, F (Subject #2 at 8 years): An indication biopsy for proteinuria shows 
prominent lobular mesangial expansion with widespread glomerular basement 
membrane (GBM) duplication (D, arrow).  Granular dense deposits in the 
duplicated GBM are seen by EM (E). Granular and segmental staining for C3 
along the GBM and in the mesangium is evident by IF, but no immunoglobulin 
was detected (F),  indicative of recurrent C3 glomerulopathy (originally classified 
as MPGN, type I)..  
G,H,I (Subject #4 at 5 years): Widespread GBM duplication (arrow) and 
glomerulitis is seen by LM (G).  EM shows prominent duplication of the GBM 
without deposits and reactive endothelial cells (H).  C4d deposition is detected in 
peritubular capillaries (I). These findings are indicative of chronic, active antibody 
mediated rejection, which at this time was subclinical.  
J,K,L (Subject #5 at 6 years): The biopsy shows minimal glomerulitis by LM (j), 
slight segmental GBM duplication by LM (J) and EM (K) and no C4d deposition 
by IF (L)   
M,N,O (Subject #6 at 2 years): LM shows normal glomeruli with rare foci of 
interstitial mononuclear inflammation affecting <5% of the cortex (M).  EM shows 
minimal focal GBM duplication and normal endothelium (N).  C4d was present in 
the majority of the peritubular capillaries (O).   
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P,Q, R (Subject #7 at 2 years): LM is within normal limits (P).  EM reveals a 
normal GBM and endothelium; foot process effacement is present in a minority of 
the capillaries (20%) (Q). There is no C4d deposition (R).   
S,T, U (Subject #9 at 2 years): The kidney biopsy is within normal limits and 
shows no evidence of rejection by LM (S) with normal glomeruli by EM (T).  
There is no evidence of recurrent MPGN.  No C4d is detected (U).   
V,W,X: (Subject #10): Indication biopsy at 9.5 months shows acute cellular 
rejection with endarteritis (V).  A protocol biopsy six months later shows complete 
resolution of the inflammatory process and residual interstitial and intimal fibrosis 
(W).  No C4d deposition is detectable at 9.5 months (X) or at other times.  
Light microscopy stains: H&E, A, M, V; PAS, D, G, J. P, S. Immunofluorescence 
stains: C4d, C, F, I, L, O, R, U, X.  
Fig. 4: Detection of donor specific antibody (DSA) 
DSAs are detected by ELISA.  
NKD03: Subject #1: DSA never detected. Subject #2: DSA transiently detected 
once at 7 years.  Subject 3: Although pre-transplant DSA was negative by ELISA, 
retrospective Luminex showed positive anti-class I DSA (B44) before 
transplantation. The subject developed acute humoral 
rejection on day10 with DSA (B44 and DR4).  
Mod NKD03: Subjects 4: Anti-donor DR17  antibody has been persistently 
positive since soon after stopping immunosuppression. Subject 5: Weak 
antidonor DR53 antibody has been intermittently detectable.   
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ITN036: In contrast to NKD03 subjects, No DSA has been detectable in any 
ITN036 subject including Subject #10 who developed severe acute cellular 
rejection.   
Fig. 5:  
A: CD3-CD19+ cell depletion after CKBMT 
In two NKD03 subjects, recovery of CD3-CD19+ cells (B cells) was found by day 
50 (Subject #1) and day 120 (Subject #2)(gray lines). With addition of two doses 
of pre-transplant rituximab (modified NKD03), B cells were partially depleted and 
recovered by days 150 and 180 (blue lines). With 4 doses of peri-transplant 
rituximab (ITN036), B cells were nearly completely depleted (less than 1-2/mm2) 
for 180 days..  
B: Serum BAFF 
Serial serum BAFF levels were measured by ELISA. Serum BAFF levels were 
less than 2 ng/ml at all time points assessed in Subject #1. Subject #2 had high 
BAFF levels initially until day 100 and humoral rejection was suspected at around 
day 45, when his BAFF level was highest (Fig. 5B). BAFF levels waned 
thereafter to less than 2 ng/ml after day 100 and he successfully discontinued his 
IS. In contrast, high BAFF levels were detected over 300 days in two subjects 
treated with the modified NKD03 regimen. Persistently high BAFF was also 
detectable for more than 300 days in the ITN036 subjects.  
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